|
|
Volumn 4, Issue 9, 2013, Pages 1332-1333
|
|
Kinase inhibitor therapy in CML: It's what's inside that counts
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCR ABL PROTEIN;
DASATINIB;
IMATINIB;
NILOTINIB;
PHOSPHOTRANSFERASE INHIBITOR;
PONATINIB;
REBASTINIB;
STAT5 PROTEIN;
APOPTOSIS;
CANCER CHEMOTHERAPY;
CHRONIC MYELOID LEUKEMIA;
DRUG EFFECT;
DRUG EXPOSURE;
DRUG HALF LIFE;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG TOLERABILITY;
EDITORIAL;
HUMAN;
PROTEIN EXPRESSION;
PROTEIN PHOSPHORYLATION;
SIGNAL TRANSDUCTION;
ANTINEOPLASTIC AGENTS;
BENZAMIDES;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
PIPERAZINES;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
|
|
EID: 84884676803
PISSN: None
EISSN: 19492553
Source Type: Journal
DOI: 10.18632/oncotarget.1271 Document Type: Editorial |
|
Times cited : (1)
|
|
References (9)
|
